(VIANEWS) – Shares of ImmunoGen (NASDAQ: IMGN) dropped 9.81% to $5.20 at 11:25 EST on Tuesday, following the last session’s upward trend. NASDAQ is jumping 2.19% to $11,440.95, following the last session’s downward trend. This seems, up until now, an all-around positive trend exchanging session today.
ImmunoGen’s last close was $5.76, 25.87% under its 52-week high of $7.77.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Earnings Per Share
As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.25.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -100.96%.
ImmunoGen’s current reported volume is 6206495, which is an 89.41% increase on its average volume (3276740).
The ImmunoGen last week’s, last month’s and quarter’s intraday variation averages were a negative 1.377%, 0.599% and 3.111%, respectively.
The highest levels of ImmunoGen’s average volatility were 5.45% (last Wednesday), 2.80%(last month) and 3.1% (last quarter).
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 38.9% and a negative 47.1%, respectively.
More news about ImmunoGen (IMGN).